Phoebe Rich

6.6k citations

116 papers · 3.8k indexed · 1 hit paper · h-index 35

Impact in

Dermatology top 0.1%
- Dermatology and Skin Diseases
- Cutaneous lymphoproliferative disorders research
- Acne and Rosacea Treatments and Effects
Immunology top 2%
- Psoriasis: Treatment and Pathogenesis

Papers in

Dermatology 64
- Cutaneous lymphoproliferative disorders research 21
- Dermatology and Skin Diseases 18
Epidemiology 72
- Nail Diseases and Treatments 66
- Fungal Infections and Studies 19

Co-authors: Richard K. Scher Boni E. Elewski David M. Pariser Helen Torok Julie Jefferson Richard Pollak J.Q. Del Rosso Mary Owens
Journals: Journal of the American Academy of Dermatology (20 papers)Journal of Dermatological Treatment (7 papers)Journal of the European Academy of Dermatology and Venereology (6 papers)Dermatologic Surgery (5 papers)Dermatologic Clinics (4 papers)
Partner nations: United States Canada Germany

In The Last Decade

Phoebe Rich

111 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial 2022 · 173 citations

Peers

Countries citing papers authored by Phoebe Rich

Since Specialization

Citations

This map shows the geographic impact of Phoebe Rich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phoebe Rich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phoebe Rich more than expected).

Fields of papers citing papers by Phoebe Rich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phoebe Rich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phoebe Rich. The network helps show where Phoebe Rich may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Phoebe Rich, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Phoebe Rich Line = papers co-authored together Phoebe Rich links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis Journal of the American Academy of Dermatology ·Andrew Blauvelt, Phoebe Rich, Howard Sofen, Bruce Strober, Joseph F. Merola, Mark Lebwohl, Akimichi Morita, Jacek C. Szepietowski, Jo Lambert, Florence de Senna Oliveira, Elizabeth Colston, 仇爱鹏, Subhashis Banerjee, Diamant Thaçi	2023	12
2	78 A Phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: Efficacy of overall and scalp psoriasis responses from FRONTIER 1 Journal of Investigative Dermatology ·Robert Bissonnette, Andreas Pinter, Laura K. Ferris, Sascha Gerdes, Phoebe Rich, Ronald Vender, Ya‐Wen Yang, Megan Miller, Yaung‐Kaung Shen, Cynthia Marie Carver DeKlotz, Kim Papp	2023	3
3	Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial Dermatology Practical & Conceptual ·Kristian Reich, Lars Erik Kristensen, Saxon D. Smith, Phoebe Rich, Christophe Sapin, Soyi Liu Leage, Robert Tracy McKenzie, Christopher Schuster, Elisabeth Riedl, Melinda Gooderham	2022	18
4	Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis Journal of Dermatological Treatment ·Kristian Reich, Curdin Conrad, Lars Erik Kristensen, Saxon D. Smith, L. Puig, Phoebe Rich, Christophe Sapin, RN Rosier, Uffe Koppelhus, Christopher Schuster	2021	24
5	Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study Journal of Dermatological Treatment ·Bárður Sigurgeirsson, Knut Schäkel, Chih-ho Hong, Isaak Effendy, Waldemar Placek, Phoebe Rich, Deborah Keefe, Gerard Bruin, Pascal Charef, Rong Fu, Isabelle Hampele, Manmath Patekar	2021	13
6	Nail Psoriasis: Diagnosis, Assessment, Treatment Options, and Unmet Clinical Needs The Journal of Rheumatology ·Gurjit S. Kaeley, Lihi Eder, Sibel Zehra Aydın, Phoebe Rich, Catherine Bakewell	2021	27
7	Efficacy and safety of mirikizumab ( LY 3074828) in the treatment of moderate‐to‐severe plaque psoriasis: results from a randomized phase II study British Journal of Dermatology ·Kristian Reich, Phoebe Rich, Catherine Maari, Robert Bissonnette, C. Leonardi, Alan Menter, Atsuyuki Igarashi, Paul Klekotka, Dipak Patel, M.W. Vooijs, Jay Tuttle, Ai Usui, Emily Edson‐Heredia, Tanzila Wasi, Kim Papp, (unknown)	2019	57
8	Immunohistochemical characterization of benign activation of junctional melanocytes and melanoma in situ of the nail unit Journal of Cutaneous Pathology ·王进谦, Josette André, Phoebe Rich, Sancy A. Leachman, Curtis Thompson	2019	8
9	Clinical trial designs for topical antifungal treatments of onychomycosis and implications on clinical practice. PubMed ·Phoebe Rich, Tracey C. Vlahovic, Warren S. Joseph, Lee T. Zane, S. Li, Disye Nectaria, Joana Cristina	2017	0
10	Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Journal of the American Academy of Dermatology ·Boni E. Elewski, Martin M. Okun, Kim Papp, Christopher Baker, Jeffrey Crowley, G. Guillet, Murali Sundaram, Yves Poulin, Yihua Gu, Ziqian Geng, David Williams, Phoebe Rich	2017	68
11	Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies Journal of the American Academy of Dermatology ·Boni E. Elewski, Raza Aly, 保彦上原, Kavita Kaur, Phoebe Rich, Rani Ragini, Z Weng, Lee T. Zane, Richard Pollak	2015	120
12	Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2) Journal of the American Academy of Dermatology ·Phoebe Rich, Melinda Gooderham, H. Bachelez, Joana Gonçalves, Robert M. Day, Цомпа Тадеуш, Jeffrey Crowley	2015	125
13	Infectious, Oncologic, and Autoimmune Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting The Journal of Rheumatology ·April W. Armstrong, Laura C. Coates, Luis R. Espinoza, Alexis Ogdie, Phoebe Rich, Enrique R. Soriano	2013	6
14	Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies Journal of the American Academy of Dermatology ·Boni E. Elewski, Phoebe Rich, Richard Pollak, David M. Pariser, Shinichi Watanabe, Hisato Senda, Ruibo Li, Kathleen Smith, Radhakrishnan Pillai, Maximilian Rod, Jason T. Olin	2012	167
15	Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year Journal of the American Academy of Dermatology ·Phoebe Rich, C.E.M. Griffiths, Kristian Reich, Frank O. Nestlé, Richard K. Scher, Shu Li, Stephen Xu, 将之世古, Cynthia Guzzo	2007	121
16	Treating cosmetically induced nail problems Dermatologic Therapy ·E. N. Podgaevskaya, Bruna Salles, Phoebe Rich	2007	14
17	Nail Cosmetics Dermatologic Clinics ·Phoebe Rich	2006	9
18	Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study* Journal of the American Academy of Dermatology ·John K. Geisse, Phoebe Rich, Amit G. Pandya, Kenneth G. Gross, Kara L. Andres, J Kaiser, Mary Owens	2002	209
19	Nail Cosmetics and Esthetics Skin Pharmacology and Physiology ·Phoebe Rich	1999	9
20	Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail Journal of the American Academy of Dermatology ·Phoebe Rich, Richard K. Scher, Debra Breneman, R Savin, Y.H.Chen, Nellie Konnikov, Jerome L. Shupack, Sheldon R. Pinnell, Norman Levine, Nicholas J. Lowe, Raza Aly, Richard B. Odom, Donald L. Greer, 石井善輝, A Bucko, Eduardo Tschen, Boni E. Elewski, Edgar B. Smith, James Hilbert	1998	31

About Phoebe Rich

Phoebe Rich is a scholar working on Dermatology, Epidemiology, Immunology, Cell Biology and Pathology and Forensic Medicine, having authored 116 papers that have together received 3.8k indexed citations. Recurring topics across this work include Nail Diseases and Treatments (66 papers), Psoriasis: Treatment and Pathogenesis (37 papers), Cutaneous lymphoproliferative disorders research (21 papers), Plant Pathogens and Fungal Diseases (20 papers), Fungal Infections and Studies (19 papers), Dermatology and Skin Diseases (18 papers), Autoimmune Bullous Skin Diseases (16 papers) and Infectious Diseases and Mycology (9 papers). The work is most often cited by research in Dermatology (2.0k citations), Immunology (1.5k citations), Epidemiology (1.9k citations), Cell Biology (828 citations) and Pathology and Forensic Medicine (619 citations). Phoebe Rich has collaborated with scholars based in United States, Canada and Germany. Frequent co-authors include Richard K. Scher, Boni E. Elewski, David M. Pariser, Helen Torok, Julie Jefferson, Richard Pollak, J.Q. Del Rosso, Mary Owens, Kara L. Andres and Amit G. Pandya. Their work appears in journals such as Journal of the American Academy of Dermatology, Journal of Dermatological Treatment, Journal of the European Academy of Dermatology and Venereology, Dermatologic Surgery and Dermatologic Clinics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact